Btg Intl patents expiration
1. Cyanokit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5834448 | BTG INTL | Dosage form of hydroxocobalamin and its use in cyanide poisoning |
Nov, 2016
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 15, 2013 |
Drugs and Companies using HYDROXOCOBALAMIN ingredient
Market Authorisation Date: 15 December, 2006
Treatment: NA
Dosage: INJECTABLE;INJECTION
CYANOKIT family patents
2. Vistogard patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968914 | BTG INTL | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Oct, 2016
(7 years ago) | |
| US6258795 | BTG INTL | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(9 months ago) | |
| US7776838 | BTG INTL | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-104) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Dec 11, 2022 |
| New Product(NP) | Dec 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2020 |
Drugs and Companies using URIDINE TRIACETATE ingredient
NCE-1 date: 05 September, 2019
Market Authorisation Date: 11 December, 2015
Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...
Dosage: GRANULE;ORAL
VISTOGARD family patents
3. Xuriden patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6258795 | BTG INTL | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Sep 04, 2022 |
| Orphan Drug Exclusivity(ODE-98) | Sep 04, 2022 |
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2020 |
Drugs and Companies using URIDINE TRIACETATE ingredient
NCE-1 date: 05 September, 2019
Market Authorisation Date: 04 September, 2015
Treatment: NA
Dosage: GRANULE;ORAL
XURIDEN family patents